SRI International Begins Second Phase of National
Institute of General Medical Sciences Grant for Mathematical Modeling
of Biological Systems Formal Method Tools Could
Dramatically Speed Drug Development and Improve Safety of New Drugs
MENLO PARK, Calif.– May 23, 2005 – SRI International,
an independent, nonprofit research and development institute, today
announced continuation of an important grant from the National Institute
of General Medical Sciences (NIGMS, a unit of the National Institutes
of Health) to model complex mammalian signaling networks based on
signaling of the epidermal growth factor receptor (EGFR).
The NIGMS grant provides support for the mathematical modeling
of complex mammalian signaling and other biological networks, using
SRI's unique formal methods tools. Promoting the mathematical modeling
of biological systems is a primary goal of NIGMS, which intends
to disseminate such tools to biologists to help them understand
the new paradigm of systems biology and to design experiments. Longer
term, these tools may prove useful in validating novel therapeutic
targets and predicting the side effects of experimental therapies.
This could dramatically speed drug development and improve
the safety of new drugs - two major issues for pharmaceutical and
biotechnology companies today.
In the project's first phase, SRI demonstrated a novel computational
approach to help researchers create, analyze, and test models of
complex EGFR signaling networks. The approach uses SRI's patent-pending
Pathway Logic (TM) pathway analysis software, based
on the Maude computer language ( http://maude.csl.sri.com/
), to model biological entities and processes. SRI developed some
of these tools as part of a Web-based Pathway Logic viewer that
allows multiple queries of graphical models of EGFR biochemistry.
In the second phase of the project, SRI will increase the utility
and predictive capabilities of Pathway Logic by enhancing the ability
of researchers to interact with the models. This phase will include
development of the Pathway Logic Assistant, an application of the
InterOperability Platform (IOP), a separately funded research project
to enable the formal methods tools written in the Maude language
to communicate and interact with each other. With IOP as the infrastructure,
SRI researchers will begin to integrate a user interface, a model
repository, new visualization tools, and various biological databases
into Pathway Logic.
The ultimate research goal of Pathway Logic is to create models
of large-scale signaling networks in defined cell types-computational
models of mammalian cells defined in terms of their molecular responses
to specific environmental signals.
"Pathway Logic models of biological systems are unique in that
they are executable-the models exist only when assembled on demand
from user-defined starting states," said Keith Laderoute, director
of SRI's Cancer Biology Program. "This feature is one
means by which Pathway Logic offers the potential for researchers
to model complex cellular networks in a familiar or intuitive way.
Ultimately, we intend to make our integrated and interactive
online Pathway Logic tools available to a wide community of biologists
and biomedical researchers. The support of NIGMS is helping to make
this possible."
About SRI International
Silicon Valley-based SRI International ( www.sri.com
) is one of the world's leading independent research and technology
development organizations. Founded as Stanford Research Institute
in 1946, SRI has been meeting the strategic needs of clients for
almost 60 years. The nonprofit research institute performs client-sponsored research and development for government agencies, commercial businesses and private foundations. In addition to conducting contract R&D,
SRI licenses its technologies, forms strategic partnerships and
creates spin-off companies.
# # #
|